SEA 0400

Drug Profile

SEA 0400

Latest Information Update: 15 Sep 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taisho Pharmaceutical
  • Class Aniline compounds; Anti-ischaemics; Phenyl ethers; Small molecules
  • Mechanism of Action Sodium-calcium exchanger inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cerebral ischaemia; Reperfusion injury

Most Recent Events

  • 15 Sep 2004 No development reported - Preclinical for Cerebral ischaemia in Japan (unspecified route)
  • 15 Sep 2004 No development reported - Preclinical for Reperfusion injury in Japan (unspecified route)
  • 16 Apr 2003 A preclinical study has been added to the Ischemic Heart Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top